# Checking if Brain Injury Drugs Work Using Saliva or Urine

> This patent describes a method to determine if a drug for brain injury is effective by measuring specific sugar molecules in a patient's saliva or urine samples over time.

- **Patent:** US 20200371093
- **Original title:** Prognostic and Diagnostic Glycan-Based Biomarkers of Brain Damage
- **Owner:** Medicortex Finland Oy
- **Status:** Active
- **Times cited:** 0
- **Field:** biotech, pharmaceutical, diagnostics, healthcare

## What it does

This patent describes a method to evaluate how well a drug treats a brain injury. First, a pharmaceutical drug is given to a patient with a brain injury. Then, samples of the patient's urine or saliva are collected at two or more different times. These samples are tested using a 'lectin array,' which is a tool containing specific proteins called lectins, such as Galanthus nivalis (GNA) or Allium sativum (ASA). The test measures the levels of certain sugar molecules, called glycans, that bind to these lectins. If the levels of these glycans change towards what is typically found in a healthy person (a 'non-brain injury control'), the drug is identified as effective. For example, if a patient with a concussion takes a new medication, and their saliva glycan levels start to resemble those of a healthy person, the drug is considered to be working.

## What it does NOT cover

- Does not cover using blood or cerebrospinal fluid samples for monitoring drug efficacy, as claims 9 and 15 specifically require urine or saliva samples.
- Does not cover methods that only diagnose a brain injury without also evaluating the effectiveness of a drug or monitoring treatment.
- Does not cover using lectins other than the specifically listed ones (GNA, ASA, NPA, PSA, DSA, PHA-L, SNA-I, HHA) to detect the glycans.
- Does not cover methods that do not involve comparing the measured glycan levels to those of a 'non-brain injury control' for efficacy determination.
- Does not cover methods that only take samples at a single time point, as the claims require samples from 'two or more time points'.

## The clever bit

The novelty lies in using specific glycan patterns, detected by a select group of lectins in non-invasive samples like urine or saliva, as a real-time indicator for how well a brain injury drug is working, moving beyond just diagnosis to actively guiding treatment.

## Real-world examples

1. Clinical trials for new traumatic brain injury (TBI) medications
2. Personalized treatment plans for concussion recovery
3. Monitoring recovery in athletes after head injuries

## Why it matters

Brain injuries like concussions and traumatic brain injury (TBI) are complex and often lack clear ways to track treatment success. This patent offers an objective method to see if a drug is actually helping, using easily collected samples like urine or saliva. This could allow doctors to personalize treatment, adjust drug dosages, and potentially improve recovery for patients.

## Frequently asked questions

### What does Checking if Brain Injury Drugs Work Using Saliva or Urine cover?

This patent describes a method to determine if a drug for brain injury is effective by measuring specific sugar molecules in a patient's saliva or urine samples over time.

### Who owns patent US 20200371093?

This patent is owned by Medicortex Finland Oy.

### When does this patent expire?

This patent is expected to expire on June 26, 2040, when the invention enters the public domain.

### What problem does this patent solve?

Brain injuries like concussions and traumatic brain injury (TBI) are complex and often lack clear ways to track treatment success. This patent offers an objective method to see if a drug is actually helping, using easily collected samples like urine or saliva. This could allow doctors to personalize treatment, adjust drug dosages, and potentially improve recovery for patients.

### What does this patent NOT cover?

Does not cover using blood or cerebrospinal fluid samples for monitoring drug efficacy, as claims 9 and 15 specifically require urine or saliva samples.

**Full plain-English explainer:** https://patentbrief.org/patent/us/20200371093/prognostic-and-diagnostic-glycan-based-biomarkers-of-brain-damage

**Original patent:** https://patents.google.com/patent/US20200371093

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._